Additionally, Bcl-xL has been linked to the acquired resistance of chronic lymphocytic leukemia (CLL) cells to ABT-199 (venetoclax), an orally bioavailable and selective Bcl-2 inhibitor approved for both treatment-naïve and relapsed CLL [45]. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.